成人生长激素缺乏症患者接受生长激素治疗的长期安全性:15 809例生长激素治疗患者概览
KIMS观察性研究纳入15 809例确诊生长激素缺乏症并接受生长激素治疗的成人及青少年患者,平均随访5.3年。不良事件报告率51.2%(治疗相关18.8%),调整后不良事件率与生长激素剂量无关;新发癌症总体发生率与一般人群相当(标准发病率比0.92;95%CI 0.83-1.01)。结论支持在常规临床实践中长期生长激素替代治疗的安全性。
要点
- 15 809例生长激素治疗患者中,51.2%报告不良事件,18.8%为治疗相关。
- 调整年龄、性别、病因和随访时间后,不良事件率与生长激素剂量无相关性。
- 新发癌症总体发生率与一般人群相当(标准发病率比0.92;95%CI 0.83-1.01)。
核心结论
- KIMS队列最终数据支持在常规临床实践中对成人生长激素缺乏症患者长期使用生长激素替代治疗的安全性。
研究设计与样本
- 全球性观察性KIMS研究纳入确诊生长激素缺乏症的成人和青少年患者,接受生长激素(Genotropin[生长激素];辉瑞,纽约)治疗并通过常规临床实践随访。
主要发现
- 共分析15 809例生长激素治疗患者,平均随访5.3年;51.2%的患者报告不良事件,其中18.8%为治疗相关。
- 年龄较大、因垂体/下丘脑肿瘤导致生长激素缺乏症或成人起病生长激素缺乏症的患者粗不良事件率更高。
- 调整年龄、性别、病因和随访时间后,不良事件率与生长激素剂量无相关性。
- 报告死亡606例(3.8%),其中肿瘤146例、心脏/血管疾病71例、脑血管疾病48例。
- 特发性/先天性生长激素缺乏症患者的新发癌症风险显著更低(标准发病率比0.64;95%CI 0.43-0.91),垂体/下丘脑肿瘤或其他病因患者与一般人群相似;成人起病或儿童起病生长激素缺乏症均与新发癌症风险增加无关。
关键数值与推荐
- 新发癌症总体标准发病率比为0.92(95%CI 0.83-1.01)。
- 特发性/先天性生长激素缺乏症患者新发癌症标准发病率比为0.64(95%CI 0.43-0.91)。
临床怎么用
- 原文未据此给出推荐。
局限性
- 原文未报告局限性。
以上解读依据论文摘要(全文未开放获取或许可不允许翻译转载)。
原文
CONTEXT: Data on long-term safety of growth hormone (GH) replacement in adults with GH deficiency (GHD) are needed. OBJECTIVE: We aimed to evaluate the safety of GH in the full KIMS (Pfizer International Metabolic Database) cohort. METHODS: The worldwide, observational KIMS study included adults and adolescents with confirmed GHD. Patients were treated with GH (Genotropin [somatropin]; Pfizer, NY) and followed through routine clinical practice. Adverse events (AEs) and clinical characteristics (eg, lipid profile, glucose) were collected. RESULTS: A cohort of 15 809 GH-treated patients were analyzed (mean follow-up of 5.3 years). AEs were reported in 51.2% of patients (treatment-related in 18.8%). Crude AE rate was higher in patients who were older, had GHD due to pituitary/hypothalamic tumors, or adult-onset GHD. AE rate analysis adjusted for age, gender, etiology, and follow-up time showed no correlation with GH dose. A total of 606 deaths (3.8%) were reported (146 by neoplasms, 71 by cardiac/vascular disorders, 48 by cerebrovascular disorders). Overall, de novo cancer incidence was comparable to that in the general population (standard incidence ratio 0.92; 95% CI, 0.83-1.01). De novo cancer risk was significantly lower in patients with idiopathic/congenital GHD (0.64; 0.43-0.91), but similar in those with pituitary/hypothalamic tumors or other etiologies versus the general population. Neither adult-onset nor childhood-onset GHD was associated with increased de novo cancer risks. Neutral effects were observed in lipids/fasting blood glucose levels. CONCLUSION: These final KIMS cohort data support the safety of long-term GH replacement in adults with GHD as prescribed in routine clinical practice.
引用
- Johannsson G, Touraine P, Feldt-Rasmussen U, et al. Long-term Safety of Growth Hormone in Adults With Growth Hormone Deficiency: Overview of 15 809 GH-Treated Patients. J Clin Endocrinol Metab. 2022. PMID: 35368070. doi:10.1210/clinem/dgac199
供执业医师工作参考,不替代临床判断;数值与分级以指南原文为准。